Effects of switching to protease inhibitor monotherapy on nucleoside analogue-related adverse events

AIDS Reviews

Volumn 16, Issue 4, 2014, Pages 236-245

  Clumeck, Nathan ^a   Hill, Andrew ^b   Moecklinghoff, Christiane ^c  

^a SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^b Biostatistics   (United Kingdom)

^c Janssen EMEA   (Germany)

Author keywords

Bone mineral density; Cholesterol; Creatinine clearance; Darunavir; Lipoatrophy; Lopinavir; Nucleoside analogue; Protease inhibitor

Indexed keywords

LIPID; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; TENOFOVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; NUCLEOSIDE; VIRUS RNA;

ANEMIA; ANTIVIRAL THERAPY; ASTHENIA; BODY COMPOSITION; BONE DENSITY; CENTRAL NERVOUS SYSTEM DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL (TOPIC); DIARRHEA; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSLIPIDEMIA; GASTROINTESTINAL TOXICITY; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; INSOMNIA; KIDNEY DYSFUNCTION; LIPOATROPHY; LIPODYSTROPHY; LIPOHYPERTROPHY; LIVER TOXICITY; META ANALYSIS; MONOTHERAPY; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; BLOOD; BODY FAT DISTRIBUTION; BONE DISEASES, METABOLIC; CHEMICALLY INDUCED; DRUG COMBINATION; DRUG EFFECTS; FOLLOW UP; HIV ASSOCIATED LIPODYSTROPHY; HIV INFECTIONS; PATHOPHYSIOLOGY; PHOTON ABSORPTIOMETRY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; VIRUS LOAD;

ABSORPTIOMETRY, PHOTON; ANEMIA; ANTI-HIV AGENTS; BODY FAT DISTRIBUTION; BONE DENSITY; BONE DISEASES, METABOLIC; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; LIPIDS; NUCLEOSIDES; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84908642002     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Pozniak A. Gallant J, DeJesus E,. Tenofovir disoproxil tumarate, emtricitabine, and etavirenz versus tixed-dose zidovudinejtamivudine and etavirenz in antiretroviral-naive patients: Virologic, immunologic, and morphologic changes-A 96-week analysis. J Acquir Immune Defic Syndr. 2006: 43: 535-40.
2. Hoetelmans ft Marien K, De Pauw M,. Pharmacokinetic interaction between TMC1 l4lritonavir and tenofovir disoproxil tumarate in healthy volunteers. Br J din Pharmacol. 2067; 64: 655-61.
3. Cooper R, Wiebe N, Smith N,. Systematic review and mets-Analysis: Renal satety of tenofovir disoproxil tumarate in HIV-infected patients. din Infect Dis. 2010; 51: 496-505.
4. Bierman w, van Agtmael M, Nijhuis M,. HIV monotherapy with ritonavir-boosted protease inhibitors: A systematic review. AIDS. 2000: 23: 279-91.
5. Mathis S, Khanlari B, Pulido F,. Effectiveness of profease inhibitor monotherapy versus combination antiretroviral maintenance therapy: A meta-Analysis. Plos One. 2011 : 6: E22003.
6. Arribas , J, Clumeck N, Nelson M,. The MONET trial: Week 14. 4 analysis ot the efficacy of darunavir/ritonavir (DF1Wr) monotherapy versus DRVIr plus two nucleoside reverse transcriptase inhibitors, for patients with viral load 50 HIV-1 RNA copieslmL at baseline. HIV Med. 2012; 13: 398-405.
7. Katlama C, Valantin M, Aigarte-Genin M,. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: A randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS. 2010: 24: 2365-74.
8. Pulido F, Arribas J, Delgado R,. Lopinavir-ritonavir monotherapy versus topinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS. 2008; 22: F1-9.
9. Cameron O, da Silva B, Arribas JR,. A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. J Infect Dis. 2008: 198: 234-40.
10. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5. 1. 0 [updated March 20111. The Cochrane Collaboration. 2011. Available at: Www. cochrane-handbook. org.
11. Brown T, Mcdomsey G, King M,. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr. 2009; 51: 554-61.
12. Ghosn J, Flandre P, Cohen-Coder I,. Long-Term (96-week) follow-up of antiretroviral-naive HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial. HIV Med. 2010: 11: 137-42.
13. Kolta S, Flandre P, Van P. Fat tissue distribution changes in HIVinfected patients treated with lopinavir/ritonavir. Results of the MONAJRK trial. Curr HIV Res. 2011: 9: 31-9.
14. Meynard J, Bouteloup V. Landman R,. Lopinavir/ritonavir mono-Therapy versus current treatment continuation for maintenance therapy of HIV-1 infection: The KALESOLO trial. J Antimicrob Chernother. 2010: 65: 2436-44.
15. Valantin MA, Lambert-Niclot S, Flandre P, et al. Long-Term efficacy of darunavir/ritonavir monofherapy in patients with HIV-1 viral suppression: Week 96 results from the MONOI ANF1S 136 study. J Ant imicixt Chernother. 2012: 67: 691-5.
16. Valantin M, Kolta S, Flandre P, et al. Body fat distribution in HIV-infected patients treated for 96 weeks with darunavir/ritonavir monotherapy versus darunaviriritonavir plus nuclanulde reverse transcriptaae inhibitors: The MONOI-ANRS136 subsfudy. HIV Med. 2012; 13: 505-15.
17. Guaraldi G, ZoneS, Cossarizze A,. Impact of switching to darunavir/ritonavir monotherapy vs. triple-Therapy on body fat redistribution and bone mass in virobgically suppressed HIV-infected adults. The MONARCH randomized controlled trial. European AIDS Conference. Belgrade, Serbia, 2011.
18. Guaraldi G, Zone S, Cossarizza A,. Switching to darunavir/ritonavir monotherapy vs. triple-Therapy on body fat redistribution and bone mass in HIV-infected adults: The Monarch randomized controlled trial. AIDS. 2014: 25: 207-12.
19. Bernardino J, Pulido F, Martinez E,. Switching to lopinavir/rifonavir with or without abacavirjlamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine. J Antimicrob Chemother. 2013: 68: 1373-81.
20. Arribas J, Horban A, Gerstoff J,. The MONET trial: Darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/nI. AIDS. 2010; 24: 223-30.
21. Clumeck N, Rieger A, Banhegyi O, et al. 96 week results from the MONET trial: A randomized comparison of darunavir/ritonavir with versus without nucteoside analogues, for patients with HIV RNA 50 copies/mt at baseline, J Antimicrob Chemother. 201166: 1878-85.
22. Catmy A, Fax C, Norris R, et al. Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: A cross-sectional study. J Infect Dis. 2009: 200: 1746-54.
23. Arribas J, Doroana M, Turner D, et al. Boosted protease inhibitor mono-Therapy in HIV-intected adults: Outputs from a pan-European expert panel meeting. AIDS Res Ther. 2013; i0: 3.
24. HaIl A, Hendry B, Nitsch O, et al. Tenofovir-Associated kidney toxicity in HIV-infected patients: A review of the evidence. Am J Kidney Dis. 201157: 773-80.
25. Haubrich R, Riddler S, DiRienzo A, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS. 2009: 23: 1109-18.
26. Moyfe G, Sabin C, Cartledge J,. A randomized comparative trial of tenofovir OF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS. 2006; 20: 2043-50.
27. Martin A, Bloch M, Amin J, ef at. Simplitication of antiretroviral therapy with tenofosir-emtricitabine or abacavir-Lamivudine: A randomized, 96-week trial. Clin Infect Dis. 2009; 49: 1591-601.
28. European AIDS Clinical Society (EACS) Guidelines. Version 7. O. Secondary European AIDS Clinical Society (EACS) Guidelines. Version 7. 0 0o tober 2013. Avatlable at: Http://www. eacsociety. org/Portals/O/GuidelinesS Online-i 31014.pdf
29. Documenfo de consenso de Gesida/Plan Nacionat sobre at Sida respecto at tratamiento antirretroviral en aduhos infectados por el virus de Ia inmunodeficiencia humana. Secondary Documento de consenso de Gesida/Plan Nacional sobre el Sida respecto at tratamiento antirretroviral en adultos infectados por eI virus de Ia inmunodeficiencia humana January 2012. Available at: Http://www. gesida-seimc. orgcientitica/fuentes/DcyRc/gesidadcyrc2oi 2-Documentoconsenso-TAR-Adutto-ver-ordenador.pdf
30. Antinori A, Marcotullio S, Ammassari A, et al. Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical manage mentof HIV-i infected persons. Update 2011. New Microbiol. 2012: 35: 113-59.
31. Paton N, Kityo C, Hoppe A, et al. A pragmatic randomized controlled strategy trial of three second-line treatment options for use in public health rollout programme settings: The Europe-Africa Research Network for Evaluation of Second-Une Therapy (EARNEST) Trial. 7e' Intemationat Conference on HIV Pathogenesis, Treatment and Prevention, June 2013, Kuala Lumpur, Malaysia [Abstr WELBBO2].
32. Bunupuradah T, Chetchotisakd P, Ananworanich J, et al. A randomized comparison of second-line lopinavir/ritonavir monotherapy versus teno fovirilopinavir/l'itonavir in patients falling NNRTI-regimens: The HIV STAR study. AntivirTher. 2012: 17: 1351-61.
33. Pulido F, Perez-Valero I, Delgado R, et al. Risk factors for loss of viro-logical suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression. Antivir Ther. 2009; i4: 95-201.
34. Guttmann C, Cusini A, Gunthard H, et al. Randomised, controted study demonstrating fatture of LPV/r monotherapy in HIV: The rele of comnpart-meet and CD4-nadir. AIDS. 2010; 24: 2347-54.
35. 35, Arribas J, Clumeck N, Nelson M, et al. The MONET trial: Week 144 anaty-sis of efticacyof darunavir/rttonavir monotherapy vemus DRV/r + 2 NRTIs, for patients with HIV RNA 50 copieslmL at baseline. HIV Med. 2012; 13: 398-405.